The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), was established on 20 April 2020 to meet the increasing demand of cellular therapy process development and product manufacturing to enable clinical utility.
ACTRIS’s vision is to be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine encompassing investigational and approved cellular therapeutics.
Advanced Cell Therapy and Research Institute, Singapore (“ACTRIS”) at National Cancer Center, Singapore (“NCCS”) Building will comprise of a current Good Manufacturing Practice (“cGMP”) Facility and a Good Tissue Practice (“GTP”) Facility that will serve to meet the increasing demand for cell, tissue and gene therapy (CTGT) products process development and manufacturing as well as related translational research in Singapore and the surrounding ASEAN region.
ACTRIS Education and Training is set up to support ACTRIS’ in one of the three aspects of its mission, that is, to equip those involved in various aspects of cellular-based therapy’s value chain with skills and knowledge. Cell therapy training is critical in stepping up cell, tissue and gene therapy work in Singapore and region and we are able to leverage on our internal expertise in process development & validation, product characterization, clinical trials, clinical care and clinical cell manufacturing for training and education.
ACTRIS provide business service support to researcher and new start-up company to help them to accelerate their project from process development up to commercialisation stage with the support from our team of in-house expert. We offer customised consultation and solution to identify gaps and mitigate the risks and challenges which hinder the product progress towards commercialisation, by looking into methodology which de-risk early phase development and accelerate the product development times.
About the Consortium for Clinical Research and Innovation Singapore (CRIS) The Consortium for Clinical Research and Innovation Singapore (CRIS), a wholly owned subsidiary of MOH Holdings, has been established in 2020 with the goal of strengthening synergies and promulgating strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health (MOH). […]